Advertisement

High-Throughput Screening of Drugs Against the Growth of Cryptosporidium parvum In Vitro by qRT-PCR

  • Haili Zhang
  • Guan ZhuEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2052)

Abstract

An effective method to quantify the parasite loads is the key to the evaluation of anti-cryptosporidial drug efficacy in vitro. However, high-throughput screening (HTS) of drugs against Cryptosporidium parvum in vitro was impractical by the labor-intensive traditional assays. Here we describe a simplified quantitative RT-PCR assay suitable for HTS of compounds and for evaluating drug efficacy against the growth of C. parvum in vitro.

Keywords

Cryptosporidium parvum In vitro cell culture Real-time quantitative RT-PCR (qRT-PCR) Drug screening 

Notes

Acknowledgments

This research was supported in part by the National Institute of Allergy and Infectious Disease of the National Institutes of Health under award number R21AI099850.

References

  1. 1.
    Bessoff K, Sateriale A, Lee KK, Huston CD (2013) Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob Agents Chemother 57(4):1804–1814.  https://doi.org/10.1128/AAC.02460-12CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Zhang H, Zhu G (2015) Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro. Front Microbiol 6:991.  https://doi.org/10.3389/fmicb.2015.00991CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cai X, Woods KM, Upton SJ, Zhu G (2005) Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob Agents Chemother 49(11):4437–4442.  https://doi.org/10.1128/AAC.49.11.4437-4442.2005CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Upton SJ, Tilley M, Brillhart DB (1994) Comparative development of Cryptosporidium parvum (Apicomplexa) in 11 continuous host cell lines. FEMS Microbiol Lett 118(3):233–236CrossRefGoogle Scholar
  5. 5.
    Upton SJ, Tilley M, Brillhart DB (1995) Effects of select medium supplements on in vitro development of Cryptosporidium parvum in HCT-8 cells. J Clin Microbiol 33(2):371–375CrossRefGoogle Scholar
  6. 6.
    Arrowood MJ, Sterling CR (1987) Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients. J Parasitol 73(2):314–319CrossRefGoogle Scholar
  7. 7.
    Suresh P, Rehg JE (1996) Comparative evaluation of several techniques for purification of Cryptosporidium parvum oocysts from rat feces. J Clin Microbiol 34(1):38–40CrossRefGoogle Scholar
  8. 8.
    Glasel JA (1995) Validity of nucleic acid purities monitored by 260nm/280nm absorbance ratios. BioTechniques 18(1):62–63PubMedGoogle Scholar
  9. 9.
    Iversen PW, Benoit Beck B, Yun-Fei Chen Y, Dere W, Devanarayan V, Eastwood BJ, Farmen MW, Iturria SJ, Montrose C, Moore RA, Weidner JR, Sittampalam GS (2012) HTS Assay Validation. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD. http://www.ncbi.nlm.nih.gov/books/NBK53196/Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Department of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical SciencesTexas A&M UniversityCollege StationUSA

Personalised recommendations